Caramella, Caroline

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and Applications

Cited by 2,472

Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 1,071

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 720

Tumour burden and efficacy of immune-checkpoint inhibitors

Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and Applications

Cited by 350

Impact of the COVID-19 crisis on imaging in oncological trials

Deroose, C. M., Lecouvet, F. E., Collette, L., Oprea-Lager, D. E., Kunz, W. G., Bidaut, L., Verhoeff, J. J. C., Caramella, C., Lopci, E., Tombal, B., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging

COVID-19 and healthcare impactsMedical Imaging Techniques and Applications

Cited by 12

9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)

Menis, J., Bironzo, P., Radj, G., Greillier, L., Monnet, I., Livi, L., Young, R., Decroisette, C., Cloarec, N., Robinet, G., et al. (2020) · Annals of Oncology

Lung Cancer Research StudiesLung Cancer Diagnosis and Treatment

Cited by 2